A Double-blind, Sponsor-Open, Placebo-controlled, Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of HU6 in High BMI Volunteers
Latest Information Update: 08 Nov 2021
At a glance
- Drugs HU 6 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Rivus Pharmaceuticals
- 01 Nov 2021 Positive results published in the Rivus Pharmaceuticals Media Release.
- 13 Aug 2021 Status changed from active, no longer recruiting to completed.
- 02 May 2021 Planned End Date changed from 30 Jun 2021 to 7 May 2021.